EICHORPublic-registry site landscape for NCT04669665, “A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide”, a Depressive Disorder, Major study sponsored by Seelos Therapeutics, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04669665 (registry record) |
| Study title | A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide |
| Official title | A 2-part Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) Administered to Adults With Major Depressive Disorder at Imminent Risk of Suicide |
| Sponsor | Seelos Therapeutics, Inc. |
| Condition(s) | Depressive Disorder, Major; Suicidal |
| Phase | PHASE2 |
| Listed sites | 21 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT04669665.
Eichor generates a preliminary site-risk snapshot for NCT04669665 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Depressive Disorder, Major trials
More from Seelos Therapeutics, Inc.
← Eichor home · All tracked trials · Depressive Disorder, Major studies · Weekly briefs
